MOTS-c (human) 是一种可穿透血脑屏障的线粒体来源多肽,通过调节 AMPK/PGC-1α 通路增强胰岛素敏感性,并抑制叶酸循环和嘌呤从头合成、升高 AICAR 水平以激活 AMPK,进而调控 Nrf2/Keap1 抗氧化通路、抑制 NF-κB 炎症通路,同时促进线粒体生物发生和能量代谢,具有改善糖脂代谢、抗氧化应激、抗炎及神经保护作用,可用于 2 型糖尿病、创伤性脑损伤、炎症性疾病及衰老相关代谢紊乱等研究(高分辨率测序的最新进展导致发现了源自线粒体基因组的独特肽,目前已鉴定出 8 种肽:护脑素、12S tRNA-c (MOTS-c) 的线粒体开放阅读框和 6 种小肽(护脑素样肽 (SHLP1-6)),所有这些肽均从线粒体释放到细胞质中,并与延长寿命和细胞活力、减少细胞凋亡和其他有益功能相关)。
产品编号: MS-G57133 纯度: 99.90% CAS No.: 1627580-64-6 分子式: C101H152N28O22S2 分子量: 2174.59
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价

产品描述

MOTS-c (human) 是一种可穿透血脑屏障的线粒体来源多肽,通过调节 AMPK/PGC-1α 通路增强胰岛素敏感性,并抑制叶酸循环和嘌呤从头合成、升高 AICAR 水平以激活 AMPK,进而调控 Nrf2/Keap1 抗氧化通路、抑制 NF-κB 炎症通路,同时促进线粒体生物发生和能量代谢,具有改善糖脂代谢、抗氧化应激、抗炎及神经保护作用,可用于 2 型糖尿病、创伤性脑损伤、炎症性疾病及衰老相关代谢紊乱等研究(高分辨率测序的最新进展导致发现了源自线粒体基因组的独特肽,目前已鉴定出 8 种肽:护脑素、12S tRNA-c (MOTS-c) 的线粒体开放阅读框和 6 种小肽(护脑素样肽 (SHLP1-6)),所有这些肽均从线粒体释放到细胞质中,并与延长寿命和细胞活力、减少细胞凋亡和其他有益功能相关)。

生物实验数据

生物活性 MOTS-c (human) is a mitochondria-derived peptide capable of crossing the blood-brain barrier that enhances insulin sensitivity by regulating the AMPK/PGC-1α pathway, and inhibits the folate cycle and de novo purine synthesis, elevating AICAR levels to activate AMPK, thereby modulating the Nrf2/Keap1 antioxidant pathway and suppressing the NF-κB inflammatory pathway while promoting mitochondrial biogenesis and energy metabolism; it possesses effects of improving glucose and lipid metabolism, antioxidant stress, anti-inflammation, and neuroprotection, and can be used for research on type 2 diabetes, traumatic brain injury, inflammatory diseases, and aging-related metabolic disorders (recent advances in high-resolution sequencing have led to the discovery of unique peptides derived from the mitochondrial genome, and 8 peptides have been identified to date: humanin, the mitochondrial open reading frame of 12S tRNA-c (MOTS-c), and 6 small peptides (humanin-like peptides (SHLP1-6)), all of which are released from mitochondria into the cytoplasm and are associated with extended lifespan and cell viability, reduced apoptosis, and other beneficial functions).
IC50 & Target

GLUT4

 

AMPK

 

AICAR

 

体外研究
(In Vitro)

基于高分辨率测序技术的应用,促成了源自线粒体基因组的独特肽的发现。目前已鉴定出八种肽:人源肽、12S tRNA-c 的线粒体开放阅读框 (MOTS-c) 以及六种短肽 (人源肽样肽 (SHLP1-6))。所有这些肽均从线粒体释放到细胞质中,并与延长寿命和细胞活力、减少细胞凋亡以及其他有益功能相关。
MOTS-c (human) (10 μM;24-72 h) 在 HEK293 细胞中激活 AMPK (Thr172 磷酸化) 及下游抗氧化蛋白 Nrf2、Keap1 表达,并抑制 MAPKs (ERK、JNK、P38) 磷酸化。

Western Blot Analysis

Cell Line: HEK293 cells
Concentration: 10 μM
Incubation Time: 24-72 h
Result: Significantly increased phosphorylation of AMPK at Thr172 and protein levels of Nrf2 and Keap1, while reducing phosphorylation of ERK, JNK, and P38.
Resulted activation of AMPK by densitometric quantification, with a 2-fold increase in p-AMPK/AMPK ratio compared to control.
Attenuated these effects by co-treatment with the AMPK inhibitor.
体内研究
(In Vivo)

MOTS-c (human) (25-50 mg/kg;腹腔注射;每日 1 次;21 天) 在雄性 C57BL/6 小鼠的创伤性脑损伤模型中,可减轻神经功能缺损,抑制脑组织 HMGB1/TLR4/NF-κB 炎症通路。
MOTS-c (human) (5 mg/kg;腹腔注射;每日 2 次;4 天) 在雄性 CD-1 小鼠的急性处理模型中,可通过招募 IL-6 和 TNF-α,减轻与肥胖和胰岛素抵抗相关炎症。
MOTS-c (human) (50 mg/kg;腹腔注射;每日 1 次;单次给药) 在雄性 ICR 小鼠的福尔马林炎症模型中,可减少舔爪时间,抑制脊髓 p-ERK/p-JNK/p-P38 及 c-fos 表达,发挥抗伤害性和抗炎作用。
MOTS-c (human) (0.5 mg/kg;腹腔注射;每日 1 次;8 周) 在雄性 Sprague-Dawley 大鼠 2 型糖尿病模型中,可降低空腹血糖、糖化血清蛋白及血脂水平,改善心肌超微结构损伤并激活心肌 AMPK/Nrf2 抗氧化通路。

Animal Model: Male C57BL/6 mice (6-8-week-old) with controlled-cortical impact (CCI)-induced traumatic brain injury model
Dosage: 25 mg/kg, 50 mg/kg (saline)
Administration: Intraperitoneal injection, once daily, for 21 days starting 1 hour post-injury
Result: At 50 mg/kg, MOTS-c reduced neurological severity scores (NSS) by 45% and improved rotarod performance (latency increased by 50%) compared to injured controls.
Brain tissue analysis showed reduced HMGB1 expression (30% decrease), TLR4/NF-κB pathway inhibition, and lower pro-inflammatory cytokines (TNF-α, IL-6) in the ipsilateral cortex.
OBB-NC formulation (3 mg/kg) showed comparable effects with enhanced BBB penetration.
Animal Model: Male ICR mice (25-30 g, 6-week-old) with Formalin-induced paw inflammation model
Dosage: 50 mg/kg (saline)
Administration: Intraperitoneal injection, 1 hour before formalin challenge, single dose
Result: Significantly reduced licking time in the late phase (phase II, 11-40 min) by 60% compared to vehicle controls.
Immunohistochemistry revealed decreased c-fos positive cells (40% reduction) in the spinal dorsal horn, with Western blot confirming suppressed phosphorylation of ERK (Thr202/Tyr204), JNK (Thr183/Tyr185), and P38 (Thr180/Tyr182) by 30-50%.
The AMPK inhibitor Compound C abolished these effects.
Animal Model: Male Sprague-Dawley rats (220-240 g, 7-week-old) with high-fat diet/streptozotocin-induced type 2 diabetes model
Dosage: 0.5 mg/kg (saline)
Administration: Intraperitoneal injection, once daily, for 8 weeks
Result: Significantly decreased fasting blood glucose (FBG) by 35%, HOMA-IR by 40%, and plasma triglycerides (TG)/total cholesterol (TC) by 25-30% compared to diabetic controls.
Reduced mitochondrial swelling and cristae damage, with increased SOD/GSH activity and upregulated p-AMPK, Nrf2, and Keap1 protein expression in the heart.
Combined with exercise, MOTS-c further enhanced glucose disposal and attenuated oxidative stress (MDA reduction by 50%).
性状 固体
颜色 White to off-white

化学信息

分子量 2174.59
分子式 C101H152N28O22S2
CAS No. 1627580-64-6

储存&溶解度

储存方式

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

H2O 中的溶解度 : ≥ 100 mg/mL (45.99 mM)

* "≥" means soluble, but saturation unknown.

可选溶剂浓度1 mg5 mg10 mg25 mg
H2O1 mM0.4599 mL2.2993 mL4.5986 mL11.4964 mL
5 mM0.0920 mL0.4599 mL0.9197 mL2.2993 mL
10 mM0.0460 mL0.2299 mL0.4599 mL1.1496 mL
15 mM0.0307 mL0.1533 mL0.3066 mL0.7664 mL
20 mM0.0230 mL0.1150 mL0.2299 mL0.5748 mL
25 mM0.0184 mL0.0920 mL0.1839 mL0.4599 mL
30 mM0.0153 mL0.0766 mL0.1533 mL0.3832 mL
40 mM0.0115 mL0.0575 mL0.1150 mL0.2874 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础